Celgene Corporation (NASDAQ:CELG) had its price target dropped by research analysts at UBS AG from $153.00 to $146.00 in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. UBS AG’s target price points to a potential upside of 20.33% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their target price for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price for the company in a research report on Thursday, August 10th. SunTrust Banks, Inc. set a $150.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. Finally, Robert W. Baird cut shares of Celgene Corporation from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $162.00 to $136.00 in a research report on Friday. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and twenty-two have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $150.43.

Shares of Celgene Corporation (NASDAQ:CELG) opened at 121.33 on Friday. The stock’s 50 day moving average is $140.79 and its 200 day moving average is $130.41. The firm has a market cap of $94.92 billion, a price-to-earnings ratio of 37.58 and a beta of 1.88. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.44 EPS. Equities analysts expect that Celgene Corporation will post $7.33 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) PT Lowered to $146.00” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/22/celgene-corporation-celg-pt-lowered-to-146-00.html.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,233 shares of company stock worth $6,268,259. Corporate insiders own 0.95% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arcadia Investment Management Corp MI raised its holdings in Celgene Corporation by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares during the last quarter. Thompson Davis & CO. Inc. raised its holdings in Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the first quarter worth $118,000. Motco raised its holdings in Celgene Corporation by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares during the last quarter. Finally, Balentine LLC raised its holdings in Celgene Corporation by 83.5% during the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 481 shares during the last quarter. Hedge funds and other institutional investors own 79.24% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.